Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Kidney Transplant II: Surgical Procedure

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...

Kidney Transplant I: Introduction

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...

Kidney Transplant III: Nursing Management

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of OKT3 Therapy on Cytomegalovirus and Herpes Simplex Virus Infections After Liver Transplantation.

Transplantation proceedings·2012

Same author

Rapid Flush Technique for Donor Hepatectomy: Safety and Efficacy of an Improved Method of Liver Recovery for Transplantation.

Transplantation proceedings·2011

Same author

Establishment of Primary Cultures of Human Biliary Epithelium and Induction of Class II Major Histocompatibility Complex Antigens by Interferon Gamma.

Transplantation proceedings·2011

Same authorSame journal

THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS.

Surgical research communications·2011

Same authorSame journal

IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION.

Surgical research communications·2011

Same author

In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs.

Transplantation proceedings·2011

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

IMMUNOSUPPRESSION WITH FR 900506 FOR CANINE KIDNEY AND LIVER TRANSPLANTATION.

S Todo¹, L Makowka, T Starzl

¹Department of Surgery, University of Pittsburgh Health Center, University of Pittsburgh, Pittsburgh, Pennsylvania.

Surgical Research Communications

|May 10, 2011

Summary

This summary is machine-generated.

FR 900506 demonstrated immunosuppressive effects in canine organ transplantation. This immunosuppressant improved survival rates in kidney and liver transplant recipients without causing organ toxicity.

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Experiment Videos

Last Updated: Jun 2, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Area of Science:

Veterinary Medicine
Immunosuppression
Transplantation Biology

Background:

Organ transplantation in canines is a critical area for studying immunosuppressive therapies.
Effective immunosuppression is vital to prevent graft rejection and improve long-term survival post-transplant.

Purpose of the Study:

To evaluate the immunosuppressive efficacy of FR 900506 in canine kidney and liver transplantation models.
To assess the impact of FR 900506 on short-term survival rates following organ transplantation.

Main Methods:

Canine kidney and liver transplant recipients were administered daily oral doses of FR 900506 (0.5, 1.0, 1.5 mg/kg).
Survival rates were monitored for one month post-transplantation.
Biochemical tests were performed to assess for hepatotoxicity and nephrotoxicity.

Main Results:

Untreated kidney recipients survived a mean of 12.1 days.
One-month survival rates for FR 900506 treated kidney recipients were 2/6, 3/6, and 4/6 for the respective doses.
One-month survival for liver recipients treated with FR 900506 was 4/5, compared to 1/8 in historical untreated controls.
No evidence of hepatotoxicity or nephrotoxicity was observed through biochemical analysis.

Conclusions:

FR 900506 exhibits significant immunosuppressive properties in canine kidney and liver transplantation.
The compound effectively enhances short-term survival rates in transplant recipients.
FR 900506 appears safe, with no detectable hepatotoxicity or nephrotoxicity in this study.